Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

被引:9
|
作者
Jia, Yaxun [1 ]
Wang, Min [1 ]
Sang, Xiaolin [1 ]
Liu, Pixu [2 ]
Gao, Jingchun [3 ]
Jiang, Kui [4 ]
Cheng, Hailing [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dalian Key Lab Mol Targeted Canc Therapy, Canc Inst, Dalian, Peoples R China
[2] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China
[3] Dalian Med Univ, Hosp 1, Dept Obstet & Gynecol, Dalian, Peoples R China
[4] Dalian Med Univ, Hosp 2, Dept Med Oncol, Dalian, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
BMN; 673; high-grade serous ovarian cancer; PARP inhibitor; phenethyl isothiocyanate; reactive oxygen species; OXIDATIVE STRESS; ORGANIC ISOTHIOCYANATES; THERAPY; RESISTANCE; COMBINATION; ONCOGENE; OLAPARIB;
D O I
10.3389/fonc.2021.812264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders may eventually become resistant. Therefore, the development of novel effective combinatorial strategies to treat HGSOC is urgently needed. Here, we report that H2O2-induced oxidative stress sensitized HGSOC cells to PARPi BMN 673. Furthermore, Phenethyl isothiocyanate (PEITC) as a ROS-inducing agent significantly enhanced the cytotoxic effects of BMN 673. Mechanistically, combined use of PEITC and BMN 673 resulted in ROS overproduction and accumulation, enhanced DNA damage, G2/M arrest and apoptosis, all of which were significantly reversed by the ROS scavenger N-Acetyl-L-cysteine. We also showed that while PEITC did not further enhance the ability of BMN 673 on PARP1 trapping in HGSOC cells, the therapeutic effects of the PEITC/BMN 673 combination were at least in part dependent on the presence of PARP1. Importantly, the PEITC/BMN 673 combination potently abrogated the growth of HGSOC tumor spheroids and patient-derived organoid models of HGSOC and cervical cancer. Our findings provide a basis for further investigation of the utility of PARPi combination regimen in HGSOC and cervical cancer through ROS-mediated mechanisms.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] PARP Inhibitors Display Differential Efficacy in Models of BRCA Mutant High-Grade Serous Ovarian Cancer
    Dickson, Kristie-Ann
    Xie, Tao
    Evenhuis, Christian
    Ma, Yue
    Marsh, Deborah J.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (16)
  • [2] Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer
    Vendrell, Julie A.
    Ban, Iulian O.
    Solassol, Isabelle
    Audran, Patricia
    Cabello-Aguilar, Simon
    Topart, Delphine
    Lindet-Bourgeois, Clothilde
    Colombo, Pierre-Emmanuel
    Legouffe, Eric
    D'Hondt, Veronique
    Fabbro, Michel
    Solassol, Jerome
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (18)
  • [3] Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
    Kanakkanthara, Arun
    Hou, Xiaonan
    Ekstrom, Thomas L.
    Zanfagnin, Valentina
    Huehls, Amelia M.
    Kelly, Rebecca L.
    Ding, Husheng
    Larson, Melissa C.
    Vasmatzis, George
    Oberg, Ann L.
    Kaufmann, Scott H.
    Mansfield, Aaron S.
    Weroha, S. John
    Karnitz, Larry M.
    CANCER RESEARCH, 2022, 82 (02) : 307 - 319
  • [4] Efficacy of PARP inhibitors in advanced high-grade serous ovarian cancer according to BRCA domain mutations and mutation type
    Buonaiuto, Roberto
    Neola, Giuseppe
    Caltavituro, Aldo
    Longobardi, Alessandra
    Mangiacotti, Federica Pia
    Cefaliello, Amedeo
    Lamia, Maria Rosaria
    Pepe, Francesco
    Ventriglia, Jole
    Malapelle, Umberto
    Troncone, Giancarlo
    Giuliano, Mario
    Arpino, Grazia
    Pignata, Sandro
    De Angelis, Carmine
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [5] Apoptosis is augmented in high-grade serous ovarian cancer by the combined inhibition of Bcl-2/Bcl-xL and PARP
    Yokoyama, Takuhei
    Kohn, Elise C.
    Brill, Ethan
    Lee, Jung-Min
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2017, 50 (04) : 1064 - 1074
  • [6] High-grade serous ovarian cancer: the clone wars
    Salomon-Perzynski, Aleksander
    Salomon-Perzynska, Magdalena
    Michalski, Bogdan
    Skrzypulec-Plinta, Violetta
    ARCHIVES OF GYNECOLOGY AND OBSTETRICS, 2017, 295 (03) : 569 - 576
  • [7] Prognostic gene expression signature for high-grade serous ovarian cancer
    Millstein, J.
    Budden, T.
    Goode, E. L.
    Anglesio, M. S.
    Talhouk, A.
    Intermaggio, M. P.
    Leong, H. S.
    Chen, S.
    Elatre, W.
    Gilks, B.
    Nazeran, T.
    Volchek, M.
    Bentley, R. C.
    Wang, C.
    Chiu, D. S.
    Kommoss, S.
    Leung, S. C. Y.
    Senz, J.
    Lum, A.
    Chow, V
    Sudderuddin, H.
    Mackenzie, R.
    George, J.
    Fereday, S.
    Hendley, J.
    Traficante, N.
    Steed, H.
    Koziak, J. M.
    Kobel, M.
    McNeish, I. A.
    Goranova, T.
    Ennis, D.
    Macintyre, G.
    De Silva, D. Silva
    Ramon y Cajal, T.
    Garcia-Donas, J.
    Hernando Polo, S.
    Rodriguez, G. C.
    Cushing-Haugen, K. L.
    Harris, H. R.
    Greene, C. S.
    Zelaya, R. A.
    Behrens, S.
    Fortner, R. T.
    Sinn, P.
    Herpel, E.
    Lester, J.
    Lubinski, J.
    Oszurek, O.
    Toloczko, A.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1240 - 1250
  • [8] Integrative prognostic subtype discovery in high-grade serous ovarian cancer
    Xie, Hongyu
    Xu, Huan
    Hou, Yan
    Cai, Yuqing
    Rong, Zhiwei
    Song, Wei
    Wang, Wenjie
    Li, Kang
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2019, 120 (11) : 18659 - 18666
  • [9] Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification
    Gasimli, Khayal
    Raab, Monika
    Rad, Morva Tahmasbi
    Kurunci-Csacsko, Elisabeth
    Becker, Sven
    Strebhardt, Klaus
    Sanhaji, Mourad
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
  • [10] HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
    Ali, Ahlam
    Zhang, Fengyu
    Maguire, Aaron
    Byrne, Tara
    Weiner-Gorzel, Karolina
    Bridgett, Stephen
    O'Toole, Sharon
    O'Leary, John
    Beggan, Caitlin
    Fitzpatrick, Patricia
    McCann, Amanda
    Furlong, Fiona
    CANCERS, 2020, 12 (12) : 1 - 20